Cyclo Therapeutics Announces Publication Of Data From Phase 2 Clinical Study Of Trappsol Cyclo For The Treatment Of Niemann-Pick Disease Type C1
Portfolio Pulse from Happy Mohamed
Cyclo Therapeutics (NASDAQ:CYTH) has published positive data from its Phase 1/2 clinical trial for Trappsol Cyclo, a treatment for Niemann-Pick Disease Type C1. The trial demonstrated promising safety and efficacy results, with an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale. The company is currently enrolling for its Phase 3 study, expected to be completed by the end of this year.
June 29, 2023 | 5:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cyclo Therapeutics has published positive data from its Phase 1/2 clinical trial for Trappsol Cyclo, a treatment for Niemann-Pick Disease Type C1. The company is currently enrolling for its Phase 3 study.
The positive data from the Phase 1/2 clinical trial is a significant milestone for Cyclo Therapeutics and could potentially boost investor confidence in the company's ability to develop effective treatments. The ongoing enrollment for the Phase 3 study indicates progress in the company's clinical development pipeline, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100